{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:58:25Z","timestamp":1761101905652},"reference-count":23,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1733,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1111\/j.1468-1293.2010.00845.x","type":"journal-article","created":{"date-parts":[[2010,5,17]],"date-time":"2010-05-17T22:00:19Z","timestamp":1274133619000},"page":"31-39","source":"Crossref","is-referenced-by-count":11,"title":["The effects of enfuvirtide therapy on body composition and metabolic parameters over 48 weeks in the TORO body imaging substudy*"],"prefix":"10.1111","volume":"12","author":[{"given":"DA","family":"Cooper","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DV","family":"Cordery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Reiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Henry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"O'Hearn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Reynes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Arast\u00e9h","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Rowell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Guimaraes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Bertasso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the TORO 1 and TORO 2 Study Groups","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,12,3]]},"reference":[{"key":"10.1111\/j.1468-1293.2010.00845.x-BIB1|cit1","first-page":"2009","article-title":"Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy","volume":"19","author":"Schneider","year":"2005","journal-title":"1984-2004"},{"key":"10.1111\/j.1468-1293.2010.00845.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1097\/00002030-200107270-00008","article-title":"Clinical assessment of HIV-associated lipodystrophy in an ambulatory population","volume":"15","author":"Lichtenstein","year":"2001","journal-title":"AIDS (London, UK)"},{"key":"10.1111\/j.1468-1293.2010.00845.x-BIB3|cit3","first-page":"293","article-title":"HIV lipodystrophy","volume":"4","author":"Miller","year":"2003","journal-title":"prevalence, severity and correlates of risk in Australia"},{"key":"10.1111\/j.1468-1293.2010.00845.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/01.qai.0000182230.47819.aa","article-title":"Fat distribution in men with HIV infection","volume":"40","author":"Bacchetti","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1111\/j.1468-1293.2010.00845.x-BIB5|cit5","first-page":"L5","article-title":"Increase in limb fat after nucleoside analogue cessation is not associated with decreased visceral fat and has different risk factors","volume":"10","author":"Wand","year":"2005","journal-title":"Antiviral Ther"},{"key":"10.1111\/j.1468-1293.2010.00845.x-BIB6|cit6","first-page":"2093","article-title":"Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus","volume":"353","author":"Carr","year":"1999","journal-title":"a cohort study"},{"key":"10.1111\/j.1468-1293.2010.00845.x-BIB7|cit7","first-page":"2441","article-title":"Failure to maintain long-term adherence to highly active antiretroviral therapy","volume":"15","author":"Duran","year":"2001","journal-title":"the role of lipodystrophy"},{"key":"10.1111\/j.1468-1293.2010.00845.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1161\/01.CIR.92.6.1430","article-title":"Combined effects of HDL cholesterol, triglyceride, and total cholesterol concentrations on 18-year risk of atherosclerotic disease","volume":"92","author":"Burchfiel","year":"1995","journal-title":"Circulation"},{"key":"10.1111\/j.1468-1293.2010.00845.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"III15","DOI":"10.1161\/01.CIR.0000131513.33892.5b","article-title":"New risk factors for atherosclerosis and patient risk assessment","volume":"109","author":"Fruchart","year":"2004","journal-title":"Circulation"},{"key":"10.1111\/j.1468-1293.2010.00845.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/jac\/dkh013","article-title":"Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients","volume":"53","author":"Calza","year":"2004","journal-title":"J Antimicrobial Chemother"},{"key":"10.1111\/j.1468-1293.2010.00845.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"F51","DOI":"10.1097\/00002030-199807000-00003","article-title":"A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors","volume":"12","author":"Carr","year":"1998","journal-title":"AIDS (London, UK)"},{"key":"10.1111\/j.1468-1293.2010.00845.x-BIB12|cit12","first-page":"1475","article-title":"Improvement of dyslipidemia in patients switching from stavudine to tenofovir","volume":"18","author":"Domingo","year":"2004","journal-title":"preliminary results"},{"key":"10.1111\/j.1468-1293.2010.00845.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1086\/339866","article-title":"Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy","volume":"34","author":"Saves","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1468-1293.2010.00845.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1097\/00002030-200105040-00005","article-title":"Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection","volume":"15","author":"Van Der Valk","year":"2001","journal-title":"AIDS (London, UK)"},{"key":"10.1111\/j.1468-1293.2010.00845.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"918","DOI":"10.2337\/diabetes.52.4.918","article-title":"Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens","volume":"52","author":"Woerle","year":"2003","journal-title":"Diabetes"},{"key":"10.1111\/j.1468-1293.2010.00845.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa062744","article-title":"Class of antiretroviral drugs and the risk of myocardial infarction","volume":"356","author":"Friis-Moller","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1468-1293.2010.00845.x-BIB17|cit17","first-page":"10","article-title":"Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus","volume":"72","author":"Zhang","year":"2002","journal-title":"Inverse Gaussian density absorption and 2-compartment disposition"},{"key":"10.1111\/j.1468-1293.2010.00845.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/01.qai.0000185314.56556.c3","article-title":"Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials","volume":"40","author":"Nelson","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1111\/j.1468-1293.2010.00845.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/01.qai.0000185313.48933.2c","article-title":"Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks","volume":"40","author":"Trottier","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1111\/j.1468-1293.2010.00845.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1056\/NEJMoa035026","article-title":"Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America","volume":"348","author":"Lalezari","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1468-1293.2010.00845.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1056\/NEJMoa035211","article-title":"Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia","volume":"348","author":"Lazzarin","year":"2003","journal-title":"N Engl J Med"},{"volume-title":"Table for Grading Severity of Adult Adverse Experiences","year":"1996","author":"AIDS Clinical Trials Group.","key":"10.1111\/j.1468-1293.2010.00845.x-BIB22|cit22"},{"key":"10.1111\/j.1468-1293.2010.00845.x-BIB23|cit23","first-page":"409","article-title":"Enfuvirtide in HIV-1-infected individuals changing therapy to a nucleoside reverse transcriptase inhibitor sparing regimen","volume":"11","author":"Dwyer","year":"2006","journal-title":"the ALLIANCE Study"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2010.00845.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1468-1293.2010.00845.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T18:21:22Z","timestamp":1625509282000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2010.00845.x"}},"subtitle":["Metabolic and morphological effects of enfuvirtide therapy"],"short-title":[],"issued":{"date-parts":[[2010,12,3]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2010.00845.x","relation":{},"ISSN":["1464-2662"],"issn-type":[{"type":"print","value":"1464-2662"}],"subject":[],"published":{"date-parts":[[2010,12,3]]}}}